Monthly subcutaneous injections of galcanezumab at either 120 mg or 300 mg were effective for preventing migraines.
Researchers have found that monthly subcutaneous injection of galcanezumab significantly reduce migraine headache days.
Monthly galcanezumab injections at 120 mg or 240 mg offer clinical benefit in reducing migraine pain.
Clinical Pain Advisor Articles
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- FDA Issues Warning to Companies Selling Kratom-Containing Products
- Recommendations Developed for Managing Postpartum Pain
- Cryoablation Efficacious for Cancer Pain, Review Finds
- Art Intervention Clinically Effective in Treating Cancer-Related Pain, Mood Symptoms
- Pain, Cognitive Dysfunction in SLE Mediated by Sleep Disturbance, Depression